论文部分内容阅读
目的:探讨拜阿斯匹林联合阿托伐他汀预防脑梗再发的临床价值。方法:收集我院自2011年1月-2014年1月收治的脑梗患者70例,随机分为对照组和观察组,每组35例,观察组给予拜阿斯匹林联合阿托伐他汀治疗,对照组给予拜阿司匹林联合非他汀类药物治疗,观察两组患者脑梗的再发情况。结果:观察组脑梗复发3例,复发率6.7%,再发平均时间(1.5±0.6)年,对照组脑梗复发7例,再发率20.0%,再发平均时间(0.8±0.3)年。观察组再发率明显低于对照组(P<0.05),再发时间明显晚于对照组(P<0.05),两组差异具有统计学意义。结论:拜阿司匹林联合阿托伐他汀预防脑梗再发效果明显优于单用拜阿司匹林,降低了脑梗再发率,提高了患者的生活质量,临床效果显著,值得临床推广和应用。
Objective: To investigate the clinical value of aspirin plus atorvastatin in the prevention of recurrent cerebral infarction. Methods: Seventy patients with cerebral infarction who were admitted to our hospital from January 2011 to January 2014 were randomly divided into control group and observation group, 35 cases in each group. The observation group was given aspirin combined with atorvastatin The patients in the control group were treated with aspirin plus non-statin, and the recurrent cerebral infarction was observed in both groups. Results: In the observation group, there were 3 cases of recurrent cerebral infarction, the recurrence rate was 6.7%, the mean recurrence time was (1.5 ± 0.6) years. In the control group, 7 cases were found with recurrent cerebral infarction. The recurrence rate was 20.0% . The recurrence rate in the observation group was significantly lower than that in the control group (P <0.05), and the recurrence time was significantly later than that in the control group (P <0.05). The differences between the two groups were statistically significant. Conclusion: The combination of aspirin and atorvastatin in prevention of recurrent cerebral infarction is superior to that of aspirin only. It can reduce the recurrent rate of cerebral infarction and improve the quality of life of patients with significant clinical effect. It is worthy of clinical promotion and application.